Knockdown of long non-coding RNA CCAT2 suppressed proliferation and migration of glioma cells

Hua Guo1, Guowen Hu1, Qing Yang2

  • 1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Oncotarget
|November 12, 2016
PubMed

Insights

Long non-coding RNA colon cancer-associated transcript 2 (CCAT2) is upregulated in glioma and promotes tumor growth. Inhibiting CCAT2 may offer a new therapeutic strategy for glioma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.
  • Colon cancer-associated transcript 2 (CCAT2) is implicated in various cancers, but its function in glioma remains unclear.

Purpose of the Study:

  • To investigate the expression and biological function of CCAT2 in glioma.
  • To explore the potential of CCAT2 as a diagnostic or therapeutic target in glioma.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) was used to measure CCAT2 expression in glioma tissues.
  • In vitro and in vivo functional assays were performed to assess the effects of CCAT2 knockdown.
  • Western blotting and other molecular techniques were employed to analyze signaling pathways.

Main Results:

  • CCAT2 expression was significantly upregulated in glioma tissues, correlating with advanced tumor stages (III/IV).
  • Knockdown of CCAT2 inhibited glioma cell proliferation, cell cycle progression, and migration.
  • CCAT2 knockdown suppressed glioma cell phenotypes by inhibiting the Wnt/β-catenin signaling pathway.

Conclusions:

  • CCAT2 plays a crucial role in glioma progression.
  • CCAT2 may serve as a potential biomarker and therapeutic target for glioma.